Search

everythinglearnresearchcommunity

for

Search:↓

Microneedling followed by applying green tea caused a burning sensation on the scalp. The user is seeking advice on whether this reaction is normal.

A woman is frustrated with her hair loss and the slow, ineffective healthcare system in Canada. She has tried treatments like minoxidil, doxycycline, and kenalog injections, but continues to experience painful inflammation and hair loss.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The user is unhappy with the results of their second hair transplant, feeling that grafts were wasted on an already transplanted hairline instead of increasing mid-scalp density. They regret stopping medications like Dutasteride, Minoxidil, and RU58841, which led to significant hair loss, and plan to restart them.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

A 23-year-old experiencing severe diffuse thinning after scalp inflammation is considering finasteride as a last resort after stopping minoxidil and using anti-inflammatory medication. Users suggest that inflammation causes temporary shedding and recommend consulting a dermatologist, with some advocating for finasteride as a reliable treatment option.

A user claims a product can treat alopecia, but others are skeptical, calling it a scam due to lack of evidence and transparency. The product is said to inhibit Type II 5-αr by 22.9%, but is considered weaker than existing DHT blockers.

RU58841 powder storage, with differing opinions on whether to store it in the freezer or at room temperature. One user prefers the freezer, while a company suggests room temperature.

A user experienced significant hair shedding and thinning 10 months post-hair transplant despite using minoxidil and topical finasteride. They are considering switching to oral finasteride or dutasteride and are also dealing with scalp conditions like seborrheic dermatitis.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

The user experienced significant hair shedding after long-term use of finasteride and dutasteride and is now considering trying RU58841 as a last resort. They have checked health factors and suspect stress and poor sleep may contribute to the shedding, but they are determined to try RU58841 to see if it helps with androgenetic alopecia.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

A user who didn't respond well to minoxidil and finasteride is considering the role of IGF-1 in hair loss treatment effectiveness. They discuss the potential of using HGH to improve hair growth and other health issues, referencing several sources that suggest IGF-1 levels may influence hair loss and treatment response.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.

RU58841 should be refrigerated. The KB Solution is more effective at delivering RU58841 to the scalp.

A 29-year-old reports positive hair recovery after 7 months using liposomal topical finasteride and minoxidil, low-level light therapy, and vitamins, following a 3600 graft DHI procedure. They experienced no side effects from the topical treatment, unlike with oral finasteride.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

The conversation is about a transgender individual's experience with hair regrowth using topical minoxidil and hormone replacement therapy (HRT), expressing concern about the slow growth and thin appearance of their hair. Some responses encourage patience and highlight the variability of results, while others discuss the role of HRT and its effects.

People are discussing making their own PP405 for hair loss treatment using JLX069 and DMSO. There is skepticism about the safety and effectiveness of this homemade solution, with some users expressing concerns about potential risks.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

The user has been using HIMS topical finasteride and minoxidil spray for hair loss, with positive results but still seeks improvement at the crown and corners. They are considering reintroducing derma rolling and possibly trying oral treatments like dutasteride due to concerns about shedding and irritation.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

The conversation is about managing an itchy, flaky scalp, possibly due to psoriasis, and the use of a hydrating conditioner to address dryness. The user is concerned about using conditioner due to experiencing telogen effluvium.

The conversation is about the appropriate wait time to apply topical finasteride after microneedling to prevent it from going systemic. The user is combining finasteride with minoxidil and is unsure whether to wait 24 or 48 hours after microneedling before applying the treatment.

A 19-year-old using topical minoxidil and dutasteride reports significant hair growth and shedding. Minoxidil caused new facial hair growth, and the user hopes for thicker hair regrowth.

The conversation discusses hair regrowth results after using finasteride, minoxidil, and dermarolling for four months. Users inquire about dosages and when results were first noticed.